Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 52,280 | 51,677 | 36,054 | 24,299 | 15,400 |
| Cost of Goods | 8,041 | 14,098 | 4,960 | 5,162 | 1,705 |
| Gross Profit | 44,239 | 37,580 | 31,094 | 19,137 | 13,695 |
| Operating Expenses | 190,569 | 191,247 | 186,286 | 171,004 | 159,946 |
| Operating Income | -146,289 | -153,570 | -154,232 | -151,705 | -145,545 |
| Interest Expense | 26,687 | 10,178 | 10,562 | -4,449 | 41,544 |
| Other Income | -2,886 | 30,869 | 47,131 | -64,039 | 16,750 |
| Pre-tax Income | -175,862 | -132,878 | -117,663 | -211,295 | -170,340 |
| Income Tax | 702 | -468 | 1,392 | 5,613 | -168 |
| Net Income Continuous | -176,564 | -132,411 | -119,055 | -216,908 | -170,172 |
| Net Income | $-176,564 | $-132,411 | $-119,055 | $-216,908 | $-170,172 |
| EPS Basic Total Ops | -3.14 | -2.36 | -2.13 | -3.87 | -3.05 |
| EPS Basic Continuous Ops | -3.14 | -2.36 | -2.12 | -3.88 | -3.05 |
| EPS Diluted Total Ops | -3.14 | -2.36 | -2.13 | -3.87 | -3.05 |
| EPS Diluted Continuous Ops | -3.14 | -2.36 | -2.12 | -3.88 | -3.05 |
| EBITDA(a) | $-141,145 | $-148,428 | $-149,352 | $-146,201 | $-141,500 |